publication date: Jan 5, 2012
|
author/source: Integra Communications Ltd
Sygnature
Discovery Ltd., a leading provider of integrated drug discovery services to the
pharmaceutical industry, and Cyprotex Discovery Ltd., the world's largest
specialist ADME-Tox/PK pre-clinical discovery and development CRO, today
announced they have entered into an extension of their highly successful
strategic alliance for a further 2 years. Under the terms of the
extension of the agreement, Sygnature and Cyprotex will expand their
collaborative sales and marketing initiative to provide a fully-integrated
discovery chemistry/ADME-Tox/DMPK service to accelerate their clients' drug
discovery projects into development.
Dr Anthony
Baxter, Chief Executive Offer at Cyprotex said,
"We are delighted to have extended our strategic
alliance with Sygnature. The quality of their work and their desire to
help customers achieve scientific success has enabled both of us to form a
formidable combined offering in medicinal chemistry-driven integrated drug
discovery and ADME-Tox services. Since we commenced this relationship
there have been several changes to both companies. Both Sygnature and
Cyprotex have expanded considerably, with Cyprotex acquiring Apredica, a Boston
based ADME-Tox specialist CRO and the assets of Cellumen Inc, through which
Cyprotex can now offer proprietary high content toxicology assays under the
Cellciphr® brand name. Sygnature have grown organically over the past two
years and recently announced the formation of a strategic alliance with
Saretius Limited, a pre-clinical experimental services company offering ‘gold
standard' models in pain, CNS disorders, inflammatory and metabolic
diseases. Our experience with Sygnature over the past year has led us
both to conclude that we can successfully deliver integrated drug discovery
services to our customers, and we wish to strengthen this offering in the
future."
Commenting
on the partnership Dr Simon Hirst, Sygnature's CEO said,
"We have found the strategic alliance
with Cyprotex to be highly beneficial to our clients over the past two years.
Working with Cyprotex is a key component of our portfolio of pre-clinical
services as we have grown and expanded to offer our clients integrated drug
discovery services. Cyprotex has an enviable reputation as a CRO which
provides premium ADME-Tox/DMPK services, so I am delighted that we will
continue working together for two more years to offer our clients an
exceptional, fully-integrated drug discovery service. At Sygnature, we
strongly believe that modern drug discovery requires the marriage of medicinal chemistry,
biology, in vitro ADME and disease-specific models. Our team of over 50
medicinal chemists are experienced in using ADME data to drive programmes
forward into proof-of-concept studies. Over the past four years,
Sygnature and Cyprotex have collaborated on a number of drug discovery
programmes for clients. We have a dedicated project manager at Cyprotex
focused on our clients' projects, and scientists from both organisations have
established a very close working relationship. I am confident that future
customers will see the benefits of working with Sygnature, Cyprotex and
Saretius, acknowledged centres of excellence in their particular fields, to
accelerate their drug discovery programmes forward into development."
About
Sygnature Discovery Limited
Sygnature
Discovery is a leading UK-based provider of integrated drug discovery
services. Sygnature employs over 50 laboratory-based medicinal chemists
and bioscientists (
in vitro
biologists) in a modern, purpose-built facility in BioCity Nottingham.
Most of these scientists have PhDs and many have 10-22 years drug discovery
experience with companies such as AstraZeneca, Pfizer, Merck and OSI
Pharmaceuticals. Sygnature's industry-experienced team adds considerable
value to clients' discovery activities by undertaking complete drug discovery
programmes and key elements of the drug discovery process, such as hit finding,
hit-to-lead and lead optimisation. Sygnature's scientists also provide
significant intellectual input into clients' projects; thereby generating novel
intellectual property. Key areas of expertise include medicinal
chemistry, bioscience, molecular modelling, ADME/toxicity (through a strategic
alliance with Cyprotex Discovery) and pre-clinical experimental services
(through a strategic alliance with Saretius).
For more see
www.sygnaturediscovery.com .
About
Cyprotex PLC
Cyprotex is
based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the
US and is listed on the AIM market of the London Stock Exchange (CRX). The
company was established in 1999 and works with more than 600 partners ranging
from small biotechs to large pharma companies. Cyprotex acquired Apredica and
the assets of Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox and PK
services, extending from early drug discovery through to IND submission. The
company's core capabilities include high quality
in vitro ADME screening services, mechanistic
toxicology and high content toxicology screening services and predictive
modelling using PBPK and QSAR techniques, including Cloe® PK for
in vivo PK
prediction.
For more information, see
www.cyprotex.com.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.